Senores Pharmaceuticals (MAINBOARD)
Dec 20, 2024 - Dec 24, 2024
| Price | ₹372 - ₹391 |
| Premium | ₹284 |
|---|---|
| Lot size | 38 |
| Allotment | Dec 26, 2024 |
| Listing | Dec 30, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 38 | 14858 | 38982 |
| sHNI | 14 | 532 | 208012 | 1322 |
| bHNI | 68 | 2584 | 1010344 | 2644 |
Last updated on 24-Dec-2024 19:20:03
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 4443818 | 434778102 | 97.84 |
| HNIs | 2221909 | 223398732 | 100.54 |
| HNIs 10+ | 1481272 | 144653764 | 97.66 |
| HNIs 2+ | 740636 | 78744968 | 106.32 |
| Retail | 1481272 | 139904334 | 94.45 |
| Employees | 75000 | 1515478 | 20.21 |
| Total | 8221999 | 799596646 | 97.25 |
Application-Wise Breakup (Approx. no. of Apps) | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 2644 | 53198 | 20.12 |
| HNIs (2-10L) | 1322 | 142233 | 107.59 |
| Retail | 38982 | 3076031 | 78.91 |
| Employee | - | 29405 | - |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIBs | 173.75 | 16999.82 | 97.84 |
| FIIs | - | 3524.08 | - |
| DIIs | - | 9844.6 | - |
| Mutual funds | - | 285.81 | - |
| Others | - | 3345.33 | - |
| HNIs | 86.88 | 8734.89 | 100.54 |
| HNIs 10+ | 57.92 | 5655.96 | 97.66 |
| HNIs 2+ | 28.96 | 3078.93 | 106.32 |
| Retail | 57.92 | 5470.26 | 94.45 |
| Employees | 2.93 | 59.26 | 20.21 |
| Total | 321.48 | 31264.23 | 97.25 |
| QIB Interest Cost per share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹51.4 | @8% ₹58.7 | @9% ₹66 | @10% ₹73.4 | @11% ₹80.7 | @12% ₹88 |
IPO Details
| Issue Size | Up to 1,48,87,723 equity shares aggregating up to ₹582.11 crores. |
| Fresh Issue | Up to 1,27,87,723 equity shares aggregating up to ₹ 500 crores. |
| Offer For Sale | Up to 2,100,000 equity shares aggregating up to ₹82.11 crores. |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE,BSE |
| Share holding pre issue | 33,265,865 Shares |
| Share holding post issue | 4,60,53,588 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 75% of the Net Issue |
| Retail Shares Offered | Not less than 10% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Key Performance Indicators
| KPI | Sep-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 8.69% | 23.60% | 20.55% |
| ROCE | 7.59% | 11.73% | 18.56% |
| RONW | 8.69% | 23.60% | 20.55% |
| EPS (basic) | 7.20 | 13.67 | 8.87 |
| P/E Pre IPO | 39.77 | ||
| P/E Post IPO | 28.21 |
Financial Details (Restated) In Crores.
| Period Ended | Sep-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 678 | 622 | 131 | 59 |
| Revenue | 183 | 217 | 39 | 15 |
| Profit After Tax | 24 | 33 | 8 | 1 |
| Net Worth | 292 | 204 | 45 | 37 |
| Total Borrowing | 242 | 248 | 61 | 14 |
About Company
Senores Pharmaceuticals Limited, incorporated on December 26, 2017, is a pharmaceutical company headquartered in Ahmedabad, Gujarat. The company focuses on the development, manufacturing, and marketing of high-quality branded generic pharmaceutical products for domestic and international markets. It has a diverse product portfolio catering to therapeutic segments such as gastrointestinal, cardiovascular, respiratory, pain management, and anti-infectives. Senores leverages its R&D capabilities to drive innovation, develop cost-effective products, and maintain regulatory compliance across global markets. The company operates with a well-established distribution network, including subsidiaries like Ratnatris Pharmaceuticals Private Limited and Havix Group, Inc. d/b/a Aavis Pharmaceuticals. It serves clients across key geographies such as the US, Europe, and emerging markets.
Equirus Capital Private Limited
Ambit Private Limited
Nuvama Wealth Management Limited
Global Market Presence: Senores has an established footprint in regulated and semi-regulated markets, which helps diversify its revenue base and reduces dependence on a single geography.
Strong R&D and Manufacturing Capabilities: The Company’s robust R&D framework enables the development of complex generics and niche pharmaceutical products. It adheres to stringent global regulatory standards, ensuring product quality.
Strategic Partnerships and Long-term Relationships: Senores has built strong, long-standing relationships with key clients, suppliers, and distribution partners, ensuring consistent revenue streams and business growth.
Regulatory Challenges: Operating in a highly regulated industry, Senores is exposed to potential delays or denials in product approvals, which can impact its ability to launch new products and grow in key markets.
Raw Material Price Volatility: The Company relies on external suppliers for active pharmaceutical ingredients (APIs) and raw materials, making it susceptible to cost fluctuations and supply chain disruptions.
Competitive Pressures: The pharmaceutical industry is highly competitive, with both established players and new entrants vying for market share. This can exert downward pressure on pricing and margins